These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38818833)

  • 1. Real-world anti-seizure treatment and adverse events among individuals living with drug-resistant focal epilepsy in the United States.
    Mao J; Takahashi K; Cheng M; Xu C; Boca A; Song Y; Dandurand A
    Epilepsia Open; 2024 Aug; 9(4):1311-1320. PubMed ID: 38818833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seizure burden and healthcare resource utilization among people living with drug-resistant focal epilepsy in the United States.
    Mao J; Song Y; Cheng M; Xu C; Boca A; Dandurand A; Takahashi K
    Curr Med Res Opin; 2024 Oct; 40(10):1727-1736. PubMed ID: 39171487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures.
    Carreño M; Gil-Nagel A; Serratosa JM; Toledo M; Rodriguez-Uranga JJ; Villanueva V
    Epilepsia Open; 2024 Jun; 9(3):1051-1058. PubMed ID: 38573131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug resistant epilepsy in the United States.
    Raspin C; Faught E; Armand J; Barion F; Pollit V; Murphy J; Danielson V
    J Med Econ; 2023; 26(1):189-199. PubMed ID: 36691763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rufinamide add-on therapy for drug-resistant epilepsy.
    Panebianco M; Prabhakar H; Marson AG
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD011772. PubMed ID: 33179247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment simplification to optimize cenobamate effectiveness and tolerability: A real-world retrospective study in Spain.
    Rodríguez-Uranga JJ; Sánchez-Caro JM; Hariramani Ramchandani R
    Epilepsia Open; 2024 Aug; 9(4):1345-1356. PubMed ID: 38800945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world antiseizure medication treatment outcomes in drug-resistant focal epilepsy patients.
    Hatoum HT; Arcona S; Mao J; Walton S
    Epilepsia Open; 2023 Dec; 8(4):1556-1565. PubMed ID: 37842746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterising people with focal drug-resistant epilepsy: A retrospective cohort study.
    Benoist C; Boccaletti S; Leach JP; Cattaneo A; Chaplin A; Antunes L; Heiman F; Sander JW
    Epilepsy Behav; 2023 Dec; 149():109540. PubMed ID: 38006844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study.
    Peña-Ceballos J; Moloney PB; Munteanu T; Doyle M; Colleran N; Liggan B; Breen A; Murphy S; El-Naggar H; Widdess-Walsh P; Delanty N
    Epilepsia; 2023 May; 64(5):1225-1235. PubMed ID: 36790345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study.
    Serrano-Castro PJ; Ramírez-García T; Cabezudo-Garcia P; Garcia-Martin G; De La Parra J
    CNS Drugs; 2024 Feb; 38(2):141-151. PubMed ID: 38265735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rufinamide add-on therapy for refractory epilepsy.
    Panebianco M; Prabhakar H; Marson AG
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011772. PubMed ID: 29691835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program.
    Weinstock A; Bebin EM; Checketts D; Clark GD; Szaflarski JP; Seltzer LE; Thiele EA; Sahebkar F
    Epilepsia Open; 2024 Oct; 9(5):1816-1825. PubMed ID: 39088193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vigabatrin add-on therapy for drug-resistant focal epilepsy.
    Bresnahan R; Gianatsi M; Maguire MJ; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD007302. PubMed ID: 32730657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Tudur Smith C; Weston J; Marson AG
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001031. PubMed ID: 29952431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
    Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
    CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.
    Nevitt SJ; Sudell M; Tudur Smith C; Marson AG
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012065. PubMed ID: 31233229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-seizure medications for Lennox-Gastaut syndrome.
    Brigo F; Jones K; Eltze C; Matricardi S
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unanticipated improvement in seizure control in drug-resistant epilepsy- real world observations.
    Moloney PB; Costello DJ
    Seizure; 2021 Jan; 84():60-65. PubMed ID: 33285361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Felbamate add-on therapy for drug-resistant focal epilepsy.
    Shi LL; Bresnahan R; Martin-McGill KJ; Dong J; Ni H; Geng J
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD008295. PubMed ID: 35914010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.